

SEPTEMBER 22, 2016 – THURSDAY MORNING MEET THE EXPERT SESSIONS

7-8 am	Antiphospholipid Antibody ELISA Tests: Technical Aspects and Interpretation Maria Laura Bertolaccini (UK) Room: TBD	Antiphospholipid Antibody ELISA Tests: Technical Aspects and Interpretation (Turkish) Bahar Artim Esen (Turkey) Room: TBD	Lupus Anticoagulant Test: Technical Aspects and Interpretation Ian Mackie (UK) Room: TBD	Lupus Anticoagulant Test: Technical Aspects and Interpretation (Turkish) Reyhan Diz Kucukkaya (Turkey) Room: TBD
---------------	--	--	---	---

SEPTEMBER 22, 2016 – THURSDAY MORNING SESSIONS

MAIN SESSION 1 Origin of Antiphospholipid Antibodies		DEEP DIVE SESSION 1 Antiphospholipid Syndrome Treatment Trends Task Force Report	
Moderators	Philip G de Groot (Netherlands), Ender Terzioğlu (Turkey), Rohan Willis (USA)	Moderators	Danieli Andrade (Brazil), Maria Tektonidou (Greece)
Room	Hall A	Room	Hall B
8.00 am	Introduction and the Role of Innate/Adaptive Immunity in aPL Production Rohan Willis (USA)	8.00 am	Introduction & Summary of the 2013 Task Force Report Maria Tektonidou (Greece)
8.25 am	The Role of Infection in aPL Production Miri Blank (Israel)	8.10 am	Is There a Role for Anti-peptide Therapy in APS? Anisur Rahman (UK)
8.50 am	Microbiota and APS Martin Kriegel (USA) (Online Presentation)	8.30 am	What is New in Anti-complement Therapy in APS? Danieli Andrade (Brazil)
9.15 am	Natural Antibodies Philip G de Groot (Netherlands)	8.50 am	Is Mechanistic Target of Rapamycin (mTOR) Inhibition an option in APS? Guillaume Canaud (France)
9.40 am	Group Conclusions	9.10 am	Statins in APS – Where do we stand? Maria Cuadrado (UK)
		9.25 am	Other Potential Future Treatment Targets in APS Maria Gerosa (Italy)
		9.40 am	Closing Remarks and Future Directions Danieli Andrade (Brazil)
9.45 am 10.30 am	Coffee Break, Exhibition, and Poster Discussions	9.45 am 10.30 am	Coffee Break, Exhibition, and Poster Discussions

MAIN SESSION 2 Mechanisms of Antiphospholipid Antibody-mediated Thrombosis		DEEP DIVE SESSION 2 International & National Collaborative Research Efforts in Antiphospholipid Syndrome	
Moderators	Ahmet Gul (Turkey), Steve Krilis (Australia), Rohan Willis (USA)	Moderators	Doruk Erkan (USA), Ronald Derksen (Netherlands)
Room	Hall A	Room	Hall B
10.30 am	General Review - aPL-mediated Thrombosis Rohan Willis (USA)	10.30 am	APS ACTION 6-year Anniversary & “Hydroxychloroquine Trial” Doruk Erkan (USA)
10.50 am	The Role of Post-Translational Modification of β_2GPI in aPL-mediated Thrombosis Steve Krilis (Australia)	11.00 am	Strategies to Recruit Patients for Rare Diseases, Curbside Consultation, and Immunity Oral Alpan (USA)
11.10 am	Cell Signaling Pathways in aPL-mediated Thrombosis Philip G de Groot (Netherlands)	11.30 am	Update on European Forum on Antiphospholipid Antibodies Denis Wahl (France)
11.30 am	The Central Role of Inflammation in aPL-mediated Thrombosis Jason Knight (USA)	11.50 am	Lessons Learned from a National APS Registry Ljudmila Stojanovich (Serbia)
11.50 am	The Role of Coagulation Pathways in aPL-mediated Thrombosis Hannah Cohen (UK)	12.10 pm	Group Conclusions
12.10 pm	Group Conclusions		
12.15 pm 1.30 pm	Lunch Break & Satellite Symposium	12.15 pm 1.30 pm	Lunch Break & Satellite Symposium
A Joint Session with Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION)			

SEPTEMBER 22, 2016 – THURSDAY NOON SATELLITE SYMPOSIUM

The Future of Antiphospholipid Antibody Testing

Moderators	Maria Laura Bertolaccini (UK), Ian Mackie (UK)
Room	HALL A
12.15 pm	Opening Remarks Maria Laura Bertolaccini (UK), Ian Mackie (UK)
12.30 pm	The Value of Microparticle Chemiluminescence Technology for aPL Testing Vittorio Pengo (Italy)
12.45 pm	β₂-Glycoprotein-I Domain-I in the Assessment of Thrombosis Risk in APS Anisur Rahman (UK)
1.00 pm	Potential for Anti-Phosphatidylserine/Prothrombin Antibodies as a Criteria Test Maria Laura Bertolaccini (UK)
1.15 pm	Lupus Anticoagulant Testing: The Value of Dilute Russell’s Viper Venom Time (dRVVT) and Silica Clotting Time (SCT) Assays Armando Tripodi (Italy)
Sponsored by INOVA Diagnostics & Instrumentation Laboratory	

SEPTEMBER 22, 2016 – THURSDAY AFTERNOON SESSIONS

MAIN SESSION 3 Mechanisms of Antiphospholipid Antibody-mediated Pregnancy Morbidity		DEEP DIVE SESSION 3 Direct Oral Anticoagulants and Antiphospholipid Syndrome	
Moderators	Pier Luigi Meroni (Italy), Ware Branch (USA)	Moderators	Ahmet Muzaffer Demir (Turkey), David Garcia (USA), Tom Ortel (USA) Nergiz Yanmaz (Turkey)
Room	Hall A	Room	Hall B
1.30 pm	General Review – Mechanisms of aPL-mediated Pregnancy Morbidity and Potential Treatment Targets Jane Salmon (USA) (Online Presentation)	1.30 pm	General Review of Direct Oral Anticoagulants (DOACs) David Garcia (USA)
1.55 pm	Antiphospholipid Antibody Internalisation into the Syncytiotrophoblast Larry Chamley (New Zealand)	2.00 pm	RAPS – Rivaroxaban in Antiphospholipid Syndrome (APS) - A prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic APS, with or without SLE Hannah Cohen (UK)
2.20 pm	Do Obstetric and Thrombotic aPL have Differential Effects Upon Target Cells? Ian Giles (UK)	2.15 pm	RAPS – Rivaroxaban in APS Pilot Trial Update - A Multicenter Feasibility Study of Rivaroxaban for Patients with APS and Prior Arterial or Venous Thrombosis Mark Crowther (Canada)
2.45 pm	Targeting β₂-Glycoprotein-I to Prevent Obstetric APS Pier Luigi Meroni (Italy)	2.30 pm	TRAPS – Rivaroxaban in Thrombotic APS Trial Update - A Prospective, Randomized Clinical Trial Comparing Rivaroxaban vs Warfarin in High Risk Patients With APS Vittorio Pengo (Italy)
3.10 pm	Group Conclusions	2.45 pm	ASTRO APS - Apixaban for the Secondary Prevention of Thromboembolism: A Prospective Randomized Outcome Pilot Study Among Patients with APS Scott Woller (USA)
		3.00 pm	Group Discussion
3.15 pm 3.45 pm	Coffee Break, Exhibition, and Poster Discussions	3.15 pm 3.45 pm	Coffee Break, Exhibition, and Poster Discussions
Partially Sponsored by an Unrestricted Educational Grant from the Barbara Volcker Center for Women & Rheumatic Diseases at Hospital for Special Surgery, New York, NY, USA		Partially Sponsored by an Unrestricted Educational Grant from BAYER®	

MAIN SESSION 4 – Abstract Recognition Award (Innovation and Excellence) Presentations		DEEP DIVE SESSION 4 - Disease Activity, Damage, Risk Scores, and Quality of Life in APS	
Moderators	Graham Hughes (UK), Takao Koike (Japan)	Moderators	Mary Carmen Amigo (Mexico), Ihsan Ertenli (Turkey), Savino Sciascia (Italy)
Room	Hall A	Room	Hall B
3.45 pm	OP01 - Gram Negative Bacterial Inflammation Ameliorated by the Plasma Protein β_2-Glycoprotein-I <u>Bill Giannakopoulos (Australia)</u> , Saijun Zhou, Gang Chen, Miao Qi1, Fatima El-Assaad, Steve A Krilis	3.45 pm	Introduction & the Importance of Damage and Risk Measurement in APS Mary-Carmen Amigo (Mexico)
4.00 pm	OP02 - Identification of Novel Genetic Susceptibility Loci in Primary APS Elizabeth Gensterblum, Travis Hughes, Manuel Martínez-Bueno, Maria Orietta Borghi, Guillermo Pons-Estel, Gerard Espinosa, Alexandra Zhernakova, Cisca Wijmenga, Ricard Cervera, Pier Luigi Meroni, Marta E Alarcón-Riquelme, <u>Amr H Sawalha (USA)</u>	4.00 pm	Damage Index in APS Ma. Victoria Goycochea-Roblec (Mexico)
4.15 pm	OP03 – Major Histocompatibility Complex Class II Alleles Influence Induction of Pathogenic aPL in a Thrombosis Mouse Model <u>Rohan Willis (USA)</u> , Elizabeth Papalardo, Zurina Romay-Penabad, Premkumar Christadoss, Chella David, Ana Laura Carrera-Marin, Elba Reyes-Maldonado, Rajani Rudrangi, Ethel Garcia-Latorre, Miri Blank, Allan R Brasier, Emilio B Gonzalez	4.15 pm	Antiphospholipid Score: A Quantitative Index for Diagnosis of APS and Predictive Marker of Thrombosis. Tatsuya Atsumi (Japan)
4.30 pm	OP04- Antiphospholipid Syndrome Neutrophils are Characterized By Overexpression of P-Selectin Glycoprotein Ligand 1, a Potential Therapeutic Target <u>Jason S Knight (USA)</u> , Patrick Coit, He Meng, Srilakshmi Yalavarthi, Paul Renauer, Robert C Grenn, Levi F Mazza, Hui Wang, Daniel T Eitzman, Amr H Sawalha	4.30 pm	Global APS Score (GAPSS) Savino Sciascia (Italy)
4.45 pm	OP05 - Antiphospholipid Antibody-Mediated Increase of Tissue Factor in Arterial Wall is Associated with Increased Thrombus Size in a Mouse Model <u>Rohan Willis (USA)</u> , Pierre Grant, Zurina Romay-Penabad, Elizabeth Papalardo, Mohammed Jamaluddin, Rajani Rudrangi, Emilio Gonzalez, Allan R Brasier	4.45 pm	Can We Measure APS Disease Activity? Anisur Rahman (UK)
5.00 pm	OP06 - Levels of Cell-bound C4d in Primary APS in Comparison to SLE <u>Maria Gerosa (Italy)</u> , Paola Lonati, Francesca Rovelli, Tania Ubiali, Paolo Macor, Maria Orietta Borghi, Pier Luigi Meroni	5.00 pm	Quality of life in APS Stephane Zuily (France)
5.15 pm	OP07 - A Patient-derived Autoimmune IgG Type Monoclonal Anticardiolipin Antibody that Binds to β_2 Glycoprotein Domain I but not to Total β_2 Glycoprotein-I Molecule <u>Kenji Oku (Japan)</u> , Yuusaku Kanetsuka, Kazumasa Ohmura, Masaru Kato, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita, Shinsuke Yasuda, Gary L Norman, Bas deLaat, Tatsuya Atsumi	5.15 pm	Group Discussion
5.30 pm	Closure	5.30 pm	Closure

SEPTEMBER 23, 2016 – FRIDAY MEET THE EXPERT SESSIONS

7-8 am	Difficult-to-treat Antiphospholipid Syndrome Graham Hughes (UK) Room: TBD	Difficult-to-treat Antiphospholipid Syndrome (Turkish) Doruk Erkan (USA) Room: TBD	Obstetric Antiphospholipid Syndrome Ware Branch (USA) Room: TBD	Antiphospholipid Antibodies/Syndrome & Lupus Paul Fortin (Canada) Room: TBD
12.30 pm 1.30 pm	Antiphospholipid Antibodies/Syndrome & Lupus (Turkish) Murat Inanc (Turkey) Room: TBD	Digital Media for Antiphospholipid Syndrome Education Laurent Phialy (France) Room: TBD		

SEPTEMBER 23, 2016 – FRIDAY MORNING SESSIONS

MAIN SESSION 5 Clinical and Prognostic Significance of “Criteria” and Non-Criteria Antiphospholipid Antibody Tests		DEEP DIVE SESSION 5 Interplay Between Lupus and Antiphospholipid Syndrome	
Moderators	Tatsuya Atsumi (Japan), Maria Laura Bertolaccini (UK), Gokhan Keser (Turkey)	Moderators	Paul Fortin (Canada), Michael Lockshin (USA), Sule Yavuz (Turkey)
Room	Hall A	Room	Hall B
8.00 am	General Overview and “Criteria” ELISA Tests Maria Laura Bertolaccini (UK)	8.00 am	Introduction to Overlapping Diseases Michael D. Lockshin (USA)
8.20 am	Lupus Anticoagulant Assay and Other Tests That May Be Relevant to Clinical Practice Ian Mackie (UK)	8.20 am	Pathophysiological/Pathogenetic Interplay Between Lupus and APS Pier Luigi Meroni (Italy)
8.40 am	Anti-phosphatidylserine/antiprothrombin Antibodies Tatsuya Atsumi (Japan)	8.40 am	The Impact of aPL in Lupus Murat Inanc (Turkey)
9.00 am	Anti-Domain I Antibodies – A Specific and Predictive Marker of Thrombosis Philip De Groot (Netherlands)	9.00 am	What Did We Learn From Hopkins Lupus Cohort About aPL/APS? Michelle Petri (USA)
9.20 am	ARA (I&E) - OP08 - Which Test is the Best Predictor of Thrombosis in Patients with aPL and Associated Autoimmune Diseases? Stéphane Zuily (France), Bas De Laat, Véronique Regnault, Pierre Kaminsky, Hilde Kelchtermans, Zakera Shums, Roger Albesa, Gary Norman, Philip G. De Groot, Anne-Christine Rat, Jacques Ninet, Nadine Magy-Bertrand, Jean-Louis Pasquali, Marc Lambert, Bernard Lorcerie, Francis Guillemin, Denis Wahl	9.20 am	OP24 - Predictors of Thrombotic Events in Patients with SLE and aPL: a Prospective 10-year Follow-up Observational Study Savino Sciascia (Italy), Anna Kuzenko, Irene Castagno, Massimo Radin, Laura Solfiatti, Maria Tiziana Bertero
9.35 am	Group Conclusions	9.25 am	Group Conclusions
9.45 am 10.30 am	Coffee Break, Exhibition, and Poster Discussions	9.45 am 10.30 am	Coffee Break, Exhibition, and Poster Discussions

MAIN SESSION 6 Definition and Epidemiology of Antiphospholipid Syndrome		DEEP DIVE SESSION 6 Guidelines for Antiphospholipid Antibody Testing	
Moderators	Gulen Hatemi (Turkey), Roger Levy (Brazil), Denis Wahl (France)	Moderators	Maria Laura Bertolaccini (UK), Katrien Devreese (Belgium), Reyhan Diz-Kucukkaya (Turkey)
Room	Hall A	Room	Hall B
10.30 am	Definition of APS Stephane Zuily (France)	10.30 am	Introduction and Overview of ISTH Lupus Anticoagulant Subcommittee Activities Bas de Laat (Netherlands) (Online Presentation)
10.50 am	Definition of Obstetric APS Guilherme De Jesus (Brazil)	10.50 am	Lupus Anticoagulant Testing Guidelines Philip G de Groot (Netherlands)
11.10 am	Definition of Catastrophic APS Ricard Cervera (Spain)	11.10 am	Solid Phase aPL ELISA Testing Guidelines Katrien Devreese (Belgium)
11.30 am	What Mimics APS? Roger Levy (Brazil)	11.30 am	The Significance of IgM Anticardiolipin and Anti-β₂-Glycoprotein-I Antibodies Denis Wahl (France)
11.50 am	Is it Possible to Differentiate Infection-induced vs Autoimmune aPL? Dirk Roggenbuck (Germany)	11.50 am	The Significance of IgA Anticardiolipin and Anti-β₂-Glycoprotein-I Antibodies Angela Tincani (Italy)
12.10 pm	Group Conclusions	12.10 pm	Conclusions and Future Collaboration Opportunities Maria Laura Bertolaccini (UK)
12.15 pm 1.30 pm	Lunch Break	12.15 pm 1.30 pm	Lunch Break
		A Joint Session with International Society of Thrombosis and Hemostasis (ISTH) Lupus Anticoagulant Subcommittee	

SEPTEMBER 23, 2016 – FRIDAY NOON COMMITTEE MEETING	
Moderators	Doruk Erkan (USA), Roger Levy (Brazil)
Room	3
12.15 pm 1.30 pm	International Congress on Antiphospholipid Antibodies Executive Committee Meeting (by invitation only)

SEPTEMBER 23, 2016 – FRIDAY AFTERNOON SESSIONS

MAIN SESSION 7 Catastrophic Antiphospholipid Syndrome		DEEP DIVE SESSION 7 Pediatric Antiphospholipid Syndrome Task Force Report	
Moderators	Ricard Cervera (Spain), Umut Kalyoncu (Turkey)	Moderators	Tadej Avcin (Slovenia), Barry Myones (USA)
Room	Hall A	Room	Hall B
1.30 pm	Catastrophic APS Task Force Report Ricard Cervera (Spain)	1.30 pm	Introduction, Task Force Report, and Future Directions Barry Myones (USA)
1.50 pm	ARA (YS) - OP18 - Catastrophic APS: Descriptive Analysis of 500 Patients from the International CAPS Registry. <u>Ignasi Rodriguez-Pinto (Spain)</u> , Yehuda Shoenfeld, Doruk Erkan, Gerard Espinosa Garriga, Ricard Cervera	1.55 pm	Neonatal APS and Beyond Cassyanne Aguiar (USA)
2.05 pm	How Do I Approach to Thrombotic Storm? Tom Ortel (USA)	2.20 pm	Pediatric APS Registries: Past, Present, and Future Tadej Avcin (Slovenia)
2.30 pm	How Do I Approach to Catastrophic APS? Ricard Cervera (Spain)	2.45 pm	Probing the North American Lupus Registries for APS Data Arzu Soybilgic (USA)
2.55 pm	ARA (I&E) - OP09 - Guideline for Diagnosis and Management of Catastrophic APS Kimberly Legault, Christopher Hillis, Elie Akl, Marc Carrier, Ricard Cervera, <u>Mark Crowther (Canada)</u> , Doruk Erkan, Gerard Espinosa, Joerg Meerpohl, Karen Moffat, Sarah O'Brien, Vittorio Pengo, Jacob Rand, Ignasi Rodriguez-Pinto, Lisa Thom, Cindy Yeung, Alfonso Iorio, Holger Schunemann	3.10 pm	Group Conclusions
3.10 pm	Group Conclusions		
3.15 3.45	Coffee Break, Exhibition, and Poster Discussions	3.15 3.45	Coffee Break, Exhibition, and Poster Discussions
In Memory of Ron Asherson and Josep Font			

MAIN SESSION 8 Pediatric Antiphospholipid Syndrome		DEEP DIVE SESSION 8 Abstract Recognition Award (Young Scholar) Presentations	
Moderators	Tadej Avcin (Slovenia), Barry Myones (USA), Seza Ozen (Turkey)	Moderators	Nigel Harris (Jamaica), Jason Knight (USA)
Room	Hall A	Room	Hall B
3.45 pm	Developmental Hemostasis Patti Massicotte (Canada)	3.45 pm	OP12 - Longitudinal Human Gut Microbial Community Profiling in APS Reveals Enrichment of a Cardiolipin-producing Taxon <u>Cassianne L. Aguiar (USA)</u> , William Ruff, Andrew Goodman, Doruk Erkan, Martin A. Kriegel
4.05 pm	Thrombotic and Non-thrombotic Neurological Manifestations in Children with aPL Ann Yeh (Canada)	4.00 pm	OP13 - A Type I Interferon Signature in Monocytes and Decreased Levels of Circulating Plasmacytoid Dendritic Cells in Patients with Primary APS <u>Lucas L van den Hoogen (Netherlands)</u> , Ruth DE Fritsch-Stork, Marjan A Versnel, Joel AG van Roon, Timothy RDJ Radstake
4.25 pm	Should We Treat Children with APS Differently? Gili Kenet (Israel) (Online Presentation)	4.15 pm	OP14 - Signaling by Mammalian Target of Rapamycin (mTORC) Highlight Pathological IgG and IgA in Systemic Lupus Erythematosus Patients with Secondary APS <u>Vinicius Domingues (USA)</u> , Robert Clancy, Sara Rasmussen, H Michael Belmont
4.45 pm	OP25 - Evidence Based Recommendations for Diagnosis and Treatment of the APS in Children - Results of the Share Initiative <u>Tadej Avcin (Slovenia)</u> , Noortje Groot, Nienke de Graeff, Brigitte Bader-Meunier, Paul Brogan, Pavla Dolezalova, Brian Feldman, Isabelle Kone-Paut, Pekka Lahdenne, Alberto Martini, Liza McCann, Seza Ozen, Clarisa Pilkington, Angelo Ravelli, Annet van Royen, Nico Wulffraat, Sylvia Kamphuis, Michael Beresford	4.30 pm	OP15 - Circulating Immune Complexes of IgA Bound to β_2 -Glycoprotein I are a Predictive Marker for Graft Loss in Patients Positive for IgA a β_2 GPI <u>Jose Angel Martinez-Flores (Spain)</u> , Manuel Serrano, Oscar Cabrera, Dolores Perez, Margarita Sevilla, Sergio Mora, Florencio Garcia, Jose Maria Morales, Antonio Serrano
5.00 pm	Long-term Follow-up of Children Born to Mothers with APS Laura Andreoli (Italy)	4.45 pm	OP16 - Development of New International Classification Criteria for APS: Phase I Item Generation Survey- Part A <u>Medha Barbhaiya (USA)</u> , Karen Costenbader, Francis Guillemain, Ray Naden, Stephane Zuily, Doruk Erkan on Behalf of the 15th International Congress on aPL, APS Classification Criteria Task Force
5.20 pm	Group Conclusions	5.00 pm	OP17 - Thrombotic, Hemorrhagic and Obstetrical Outcomes During Pregnancy and the Post-Partum Period In APS <u>Cécile Marie Yelnik (France)</u> , Nathalie Costedoat-Chalumeau, Véronique Le Guern, Jean-Louis Bacri, Marta Guerra, Geoffrey Urbanski, Nathalie Morel, Gaëlle Guettrot-Imbert, David Launay, Eric Hachulla, Pierre-Yves Hatron, Jane E Salmon, Marc Lambert
		5.15 pm	Award Ceremony
5.30 pm	Closure	5.30 pm	Closure
In Memory of Silvia Pierangeli and Aziz Gharavi			

SEPTEMBER 24, 2016 – SATURDAY MEET THE EXPERT SESSIONS

7-8 am	Catastrophic Antiphospholipid Syndrome Ricard Cervera (Spain) Room: TBD	Catastrophic Antiphospholipid Syndrome (Turkish) Doruk Erkan (USA) Room: TBD	Pediatric Antiphospholipid Syndrome Tadej Avcin (Slovenia) Room: TBD	Pediatric Antiphospholipid Syndrome (Turkish) Arzu Soybilgic (USA) Room: TBD
-------------------	--	---	---	---

SEPTEMBER 24, 2016 – SATURDAY MORNING SESSIONS

MAIN SESSION 9 Prevention and Treatment of Thrombotic Antiphospholipid Syndrome:		DEEP DIVE SESSION 9 Natural Proteins Involved in Antiphospholipid Syndrome	
Moderators	Mark Crowther (Canada), Doruk Erkan (USA), Vedat Hamuryudan (Turkey)	Moderators	Philip G de Groot (Netherlands), Steve Krilis (Australia)
Room	Hall A	Room	Hall B
8.00 am	General Review - Primary Thrombosis Prevention Doruk Erkan (USA)	8.00 am	Introduction & General Review Philip G de Groot (Netherlands)
8.20 am	General Review – Secondary Thrombosis Prevention Mark Crowther (Canada)	8.20 am	The Structure and Post-Translational Modification of β_2 -Glycoprotein-I Steve Krilis (Australia)
8.40 am	Importance of Cardiovascular Disease Prevention in APS Ian Bruce (UK)	8.40 am	Reimagining APS Through the Door of Imaging: The Role of Macro-immune Complexes in APS Jacob Rand (USA)
9.00 am	Can we Stop Anticoagulation in APS Patients with Previous Thrombosis? David Garcia (USA)	9.00 am	Small angled X-ray Scattering of β_2 -Glycoprotein-I Bas de Laat (Netherlands) (Online Presentation)
9.20 am	Hydroxychloroquine in APS – Where do we stand? Maria G. Tektonidou (Greece)	9.20 am	Platelet-derived Chemokine and Endothelial Cell Interaction in APS Panayiotis Vlachoyiannopoulos (Greece)
9.40 am	Group Conclusions	9.40 am	Group Conclusions
9.45 am 10.30 am	Coffee Break, Exhibition, and Poster Discussions	9.45 am 10.30 am	Coffee Break, Exhibition, and Poster Discussions

MAIN SESSION 10 Prevention & Treatment of Obstetric Antiphospholipid Syndrome		DEEP DIVE SESSION 10 New Generation Antiphospholipid Antibody Tests	
Moderators	Ware Branch (USA), Guilherme De Jesus (Brazil)	Moderators	Maria Laura Bertolaccini (UK), Bahar Artim Esen (Turkey)
Room	Hall A	Room	Hall B
10.30 am	Assessment of Fetal Death - The Role of aPL and Other Confounding Factors Robert Silver (USA)	10.30 am	Anti- β_2 -Glycoprotein-I/HLA class II Complex Antibodies in APS Hisashi Arase (Japan)
10.55 am	What is the Impact of Treatment in Obstetric APS? Ware Branch (USA)	10.50 am	Anti-Domain IV/V Antibodies Pier Luigi Meroni (Italy)
11.20 am	ARA (I&E) – OP10 - Antiphospholipid Antibodies in Women with Preterm Delivery for Preeclampsia or Placental Insufficiency (PREPI) Karen J. Gibbins (USA), Anne E. Tebo, Samantha Nielsen, D. Ware Branch	11.10 am	Annexin A5 Resistance Assay and Alternative Functional Assays Jacob Rand (USA)
11.35 am	ARA (I&E) – OP11 - Recurrent Pregnancy Loss in Women with and without aPL Karen J. Gibbins (USA), Lindsey A. Sjaarda, D. Ware Branch, Sunni L. Mumford, Neil J. Perkins, Enrique F. Schisterman, Robert M. Silver	11.30 am	Thrombin Generation Tests for Functional Effects of aPL Denis Wahl (France)
11.50 pm	OP26 - Beneficial Effects of Pravastatin in the Management of Obstetric APS Refractory to Antithrombotic Therapy Eleftheria Lefkou, Apostolos Mamopoulos, Themistoklis Dagklis, Christos Vosnakis, David Rouso, <u>Guillermina Girardi (UK)</u>	11.45 am	Anti-Factor X Antibodies Bahar Artim Esen (Turkey)
12.05 pm	Group Conclusions	12.00 pm	APhL Enzyme-linked Immunosorbent Assay (ELISA) Rohan Willis (USA)
12.15 pm 1.30 pm	Lunch Break & Satellite Symposium	12.15 pm 1.30 pm	Lunch Break & Satellite Symposium

SEPTEMBER 24, 2016 – SATURDAY PATIENT WORKSHOP**Antiphospholipid Syndrome and Systemic Lupus Erythematosus**

Moderators	English Joann Vega (USA) Room 3 Turkish Ayten Yazici (Turkey) Room 4
Speakers	Bahar Artim Esen (Turkey), Doruk Erkan (USA), Murat Inanc (Turkey), Arzu Soybilgic (USA)
10.30 am 12.15 pm	<p>Introduction</p> <p>Basic Immunology for Antiphospholipid Syndrome & Lupus Patients</p> <p>Antiphospholipid Syndrome & Lupus:</p> <ul style="list-style-type: none"> • Clinical Manifestations • Kidney Disease • Management • Damage and Prevention Strategies • Pregnancy • Importance of Drug Adherence • Pediatric Antiphospholipid Syndrome & Lupus • Questions & Answers
Sponsored by an Educational Grant from Creaky Joints	

SEPTEMBER 24, 2016 – SATURDAY NOON SATELLITE SYMPOSIUM**Antiphospholipid Syndrome and Systemic Lupus Erythematosus**

Moderators	Doruk Erkan (USA), Murat Inanc (Turkey)
Room	Hall A
12.15 pm	<p>Introduction Doruk Erkan (USA), Murat Inanc (Turkey)</p>
12.30 pm	<p>Are There Lessons Learned from Lupus Clinical Trials that are Applicable to Antiphospholipid Syndrome? Richard Furie (USA)</p>
1.15 pm	Questions & Answers
Sponsored by an Unrestricted Educational Grant from GSK	

SEPTEMBER 24, 2016 – SATURDAY AFTERNOON SESSIONS

MAIN SESSION 11 Management of Non-Criteria Manifestations in Antiphospholipid Syndrome		DEEP DIVE SESSION 11 Antiphospholipid Syndrome Classification Criteria Task Force Report	
Moderators	Danieli Andrade (Brazil), Richard Furie (USA), Michelle Ugolini (Brazil)	Moderators	Doruk Erkan (USA), Sedat Kiraz (Turkey), Stephane Zuily (France)
Room	Hall A	Room	Hall B
1.30 pm Case Presenter: Expert Opinion:	Antiphospholipid Antibody Nephropathy Maria G. Tektonidou (Greece) Maria G. Tektonidou (Greece)	1.30 pm	Sapporo APS Classification Criteria: Historical Perspective Takao Koike (Japan)
1.55 pm Case Presenter: Expert Opinion:	Severe Thrombocytopenia Michelle Ugolini (Brazil) Reyhan Diz Kucukkaya (Turkey)	1.50 pm	Strengths and Limitations of Updated Sapporo APS Classification Criteria Ronald Derksen (Netherlands)
2.20 pm Presenter: Expert Opinion:	Cardiac Valve Disease Ozan Unlu (Pre-recorded, USA) Mary Carmen Amigo (Mexico)	2.10 pm	14th International Congress on aPL Task Force Report on “Non-criteria” Clinical Manifestations Roger Levy (Brazil)
2.45 pm Presenter: Expert Opinion:	Skin Ulcers Michelle Ugolini (Brazil) Kurosh Parsi (Australia)	2.30 pm	15th International Congress on aPL New APS Classification Criteria Initiative – Where Do We Stand? Doruk Erkan (USA)
3.10 pm	Group Conclusions	2.50 pm	Meta-analyses in APS: What Do We Know and How Do They Help Us Develop New Classification Criteria? Denis Wahl (France)
		3.10 pm	Group Conclusions
3.15 3.45	Coffee Break, Exhibition, and Poster Discussions	3.15 3.45	Coffee Break, Exhibition, and Poster Discussions

MAIN SESSION 12 Neuropsychiatric Antiphospholipid Syndrome		DEEP DIVE SESSION 12 Oral (Podium) Abstract Presentations	
Moderators	Servet Akar (Turkey), Maria Laura Bertolaccini (UK), Doruk Erkan (USA)	Moderators	Ali Akdogan (Turkey), Anisur Rahman (UK)
Room	Hall A	Room	Hall B
3.45 pm	Antiphospholipid Antibodies & Brain: Neuroimaging Findings Simone Appenzeller (Brazil)	3.45 pm	OP19 - The First Genome-Wide Association Study Identifying TSHR as A New Susceptibility Locus for Obstetric APS <u>Mayumi Sugiura-Ogasawara (Japan)</u> , Yosuke Omae, Minae Kawashima, Licht Toyo-oka, Seik-Soon Khor, Hiromi Sawai, Tetsuya Horita, Tatsuya Atsumi, Atsuko Murashima, Tamao Kitaori, Kinue Katano, Yasuhiko Ozaki, Katsushi Tokunaga
4.05 pm	Antiphospholipid Antibodies & Brain: Non-vascular Manifestations & Treatment Options Giovanni Sanna (UK)	4.00 pm	PP044 (Late-breaking Abstract) - PEGylated DI Inhibits Thrombosis in a Mouse Model of APS Thomas Christopher Richard McDonnell, Rohan Willis, Charis Pericleous, Zurina Romay-Penabad, Ian Giles, Yiannis Ioannou, Elizabeth Papalardo, <u>Anisur Rahman (UK)</u>
4.25 pm	Antiphospholipid Antibodies & Cognitive Dysfunction: Clinical Perspectives Elizabeth Kozora (USA)	4.15 pm	OP20 - Early Endosome as a Potential Target for Phosphatidylethanolamine-Binding Agents Songwang Hou, Heike Folsch, Steven E Johnson, Ke Ke, <u>Ming Zhao (USA)</u>
4.45 pm	Antiphospholipid Antibodies & Cognitive Dysfunction: Potential Mechanisms and the Effect of aPL in Mouse Fetal Brain Development Guillermina Girardi (UK)	4.30 pm	OP21 - The Clinical Relevance of Antibodies Against Domain 1 and Domain 4/5 of β_2 Glycoprotein I in Obstetric APS <u>Cecilia Beatrice Chighizola (Italy)</u> , Laura Andreoli, Marta Tonello, Maria Gabriella Raimondo, Francesca Pregnolato, Cecilia Nalli, Elena Mattia, Laura Cesana, Rajesh Kumar, Chiara Comerio, Claudia Grossi, Francesco Mombelli, Maria Gerosa, Maria Orietta Borghi, Amelia Ruffatti, Angela Tincani, Pier Luigi Meroni
5.05 pm	Group Conclusions	4.45 pm	OP22 – Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein I are Strongly Associated with The Occurrence of Acute Thrombotic Events <u>Jose Angel Martinez-Flores (Spain)</u> , Oscar Cabrera, Manuel Serrano, Dolopres Perez, Margarita Sevilla Sergio Mora, Rosa Ayala, Luis Morillas, Jose Maria Morales, Antonio Serrano
		5.00 pm	OP23 - Circulating Endothelial Cells Can Identify Patients with Antiphospholipid-Antibodies at Risk for Thrombosis <u>Stéphane Zuily (France)</u> , Marie Heymonet, Tu Qian, Marcelo De Carvalho, Gilbert Faure, Denis Wahl
5.15 5.30	Congress Closing Remarks	5.15 5.30	Congress Closing Remarks